Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus

Clinical Drug Investigation

Volumn 28, Issue 4, 2008, Pages 199-210

  Giugliano, D ^a   Ceriello, A ^b,c   Razzoli, E ^d   Esposito, K ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^c INRCA   (Italy)

^d Eli Lilly Italia   (Italy)

Author keywords

Hyperglycaemia; Insulin lispro, therapeutic use; Insulin neutral protamine lispro insulin lispro, therapeutic use; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HUMALOG NPL; HYPERGLYCEMIC AGENT; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; POSTPRANDIAL PERIOD;

EID: 40949130548     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828040-00001     Document Type: Review

References (65)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12
2. Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43 (8): 960-7
3. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998; 19 (5): 583-92
4. Haller H. The clinical importance of postprandial glucose. Diabetes Res Clin Pract 1998; 40 Suppl.: S43-9
5. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003; 163 (11): 1306-16
6. Giugliano D, Marfella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-90
7. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-01
8. Marfella R, Quagliaro L, Nappo F, et al. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108: 635-6
9. Scognamiglio R, Negut C, De Kreutzenberg SV, et al. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005; 112: 179-84
10. Esposito K, Giugliano D, Nappo F, et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-9
11. Zimmerman BR. Postprandial hyperglycemia: implications for practice. Am J Cardiol 2001; 88 (6A): 32H-6H
12. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 2000; 30 Suppl. 2: 3-11
13. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998; 15 (3): 188-93
14. Ceriello A, Davidson J, Hanefeld M, et al. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006; 16 (7): 453-6
15. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997; 14 Suppl. 3: S6-11
16. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001; 44 (12): 2107-14
17. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402
18. Torlone E, Fanelli C, Rambotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994; 37: 713-20
19. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006; 29 Suppl. 1: S4-S42
20. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16 (9): 716-30
21. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: Department of Noncommunicable Disease Surveillance, 1999
22. Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30 (2): 263-9
23. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26 (3): 881-5
24. Chiasson JL, Josse RG, Gomis R, et al. for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359 (9323): 2072-7
25. Chiasson JL, Josse RG, Gomis R, et al. for the STOP-NIDDM Trial Research Group. Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004; 47 (6): 969-75
26. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-8
27. Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metabolism 2006; 55 (9): 1263-81
28. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39 (12): 1577-83
29. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354 (9179): 617-21
30. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21 (3): 360-7
31. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 Suppl. 2: B21-9
32. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14): 977-86
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53
34. Malmberg K, for the DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314 (7093): 1512-5
35. European Diabetes Policy Group 1998. A desktop guide to type 1 (insulin-dependent) diabetes mellitus. Diabet Med 1999; 16 (3): 253-66
36. Ratner RE. Controlling postprandial hyperglycemia. Am J Cardiol 2001; 88 (6A): 26H-31H
37. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28 (2): 103-17
38. Edelman SV, Morello CM. Strategies for insulin therapy in type 2 diabetes. South Med J 2005; 98 (3): 363-71
39. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281 (21): 2005-12
40. Barnett AH. How well do rapid-acting insulins work in obese individuals? Diabetes Obes Metab 2006; 8 (4): 388-95
41. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25 (2): 330-6
42. Vazquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol 2004; 26 (6): 445-61
43. Simpson D, McCormack PL, Keating GM, et al. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs 2007; 67 (3): 407-34
44. Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 2004; 64 (17): 1957-74
45. Robinson DM, Wellington K. Insulin glulisine. Drugs 2006; 66 (6): 861-9
46. Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003; 63 (16): 1743-78
47. Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004; 64 (22): 2577-95
48. Soran H, Younis N. Insulin detemir: a new basal insulin analogue. Diabetes Obes Metab 2006; 8 (1): 26-30
49. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007; 77 (1): 1-15
50. Anderson Jr JH, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157 (11): 1249-55
51. Anderson Jr JH, Brunelle RL, Koivisto VA, et al. for the Multicenter Insulin Lispro Study Group. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997; 19 (1): 62-72
52. Vignati L, Anderson Jr JH, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther 1997; 19 (6): 1408-21
53. Altuntas Y, Ozen B, Ozturk B, et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes Obes Metab 2003; 5 (6): 371-8
54. Ross SA, Zinman B, Campos RV, et al. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001; 24 (6): 292-8
55. Bastyr 3rd EJ, Johnson ME, Trautmann ME, et al. for the IOCE Study Group. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999; 21 (10): 1703-14
56. Bastyr 3rd EJ, Stuart CA, Brodows RG, et al. for the IOEZ Study Group. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000; 23 (9): 1236-41
57. Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005; 22 (4): 374-81
58. Jacober SJ, Scism-Bacon JL, Zagar AJ, et al. A comparison of intensive mixture therapy with basal insulin therapy in insulin-näive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8: 448-55
59. Kazda C, Hülstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006; 20 (3): 145-52
60. Roach P, Yue L, Arora V, et al. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22 (8): 1258-61
61. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007; 29 (11): 2349-64
62. Coscelli C, Iacobellis G, Calderini C, et al. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol 2003; 40 (4): 187-92
63. Turco AA, De Natale C, Nosso G, et al. Efficacia terapeutica di Humalog Mix50 TID in pazienti diabetici tipo 2. Comunicazione al 7° Congresso Nazionale DEI Duemila 2006, Vil-lasimius (Cagliari), 27 Maggio 2006. CIC Edizioni Internazionali, Roma 2006
64. Leiter LA, Ceriello A, Davidson JA, et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27 Suppl. B: S42-56
65. Mayfield JA. White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004; 70 (3): 489-500 [published erratum appears in Am Fam Physician 2004; 70 (11): 2079-80]